Influenza Diagnostics Market to Reach US$ 7.6 Billion by 2029 at 12.3% CAGR, Driven by Molecular Diagnostics (60%), Type A Flu Testing (50%), Diagnostic Labs (40%), North America (35%), and Key Players Including Abbott Laboratories, Roche Diagnostics, The

The Influenza Diagnostics Market reached approximately US$ 4.1 billion in 2024 and is expected to grow to around US$ 7.6 billion by 2029, expanding at a CAGR of about 12.3% from 2025 to 2029 as healthcare providers and public health systems worldwide intensify efforts to improve detection, surveillance, and management of influenza infections.

Growth is supported by increasing demand across key test types such as rapid antigen tests, molecular assays (PCR), and point‐of‐care diagnostics, driven by the need for fast, accurate, and decentralized testing to differentiate influenza from other respiratory illnesses. Integration of advanced technologies including high‐sensitivity multiplex platforms, automated systems, and digital reporting tools further enhances diagnostic accuracy and workflow efficiency. Additionally, heightened awareness of seasonal influenza, expansion of screening programs, and strengthened healthcare infrastructure continue to propel broad adoption of influenza diagnostic solutions across hospitals, clinics, laboratories, and community testing sites globally.

Download your exclusive sample report today (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/influenza-diagnostics-market?sindhuri

Influenza Diagnostics Market: Competitive Intelligence
Abbott Laboratories, Roche Diagnostics (F. Hoffmann‐La Roche Ltd.), Thermo Fisher Scientific Inc., Siemens Healthineers, BD (Becton, Dickinson and Company), Quidel Corporation, Hologic Inc., bioMérieux SA, Danaher Corporation (Cepheid), PerkinElmer Inc., and others.
The Influenza Diagnostics Market is strongly driven by leading global diagnostics and life‐science companies such as Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientific Inc., Siemens Healthineers, and BD (Becton, Dickinson and Company), who develop and supply a comprehensive range of influenza detection solutions including rapid antigen tests, molecular PCR assays, point‐of‐care platforms, multiplex respiratory panels, and high‐throughput laboratory systems that enable rapid and accurate detection of influenza A and B viruses in clinical and decentralized settings. Their offerings help clinicians and public health authorities rapidly identify influenza infections, guide treatment decisions, and support surveillance efforts during seasonal outbreaks and pandemic scenarios.
Rising global incidence of influenza infections, ongoing respiratory disease surveillance, increased demand for rapid and high‐sensitivity diagnostic solutions, and integration of influenza testing into broader multiplex respiratory panels (covering SARS‐CoV‐2, RSV, and other pathogens) are key factors fueling market growth. Additionally, continuous technological innovations in portable and connected point‐of‐care devices, automated PCR platforms, and digital integration with healthcare records are improving accessibility, turnaround times, and data reporting across healthcare ecosystems.
These companies' complementary strengths broad diagnostic portfolios and global distribution networks from Abbott, Roche, and Thermo Fisher; advanced immunoassay and molecular testing platforms from Siemens Healthineers and BD; rapid and point‐of‐care innovations from Quidel and Hologic; multiplex respiratory panel expertise from bioMérieux and Danaher (Cepheid); and specialized influenza assay technologies from PerkinElmer enhance competitive positioning across clinical, laboratory, and decentralized testing environments. Strategic focus areas include development of next‐generation molecular and antigen assays, integrated multi‐pathogen respiratory panels, AI‐enabled interpretation and connectivity, expansion of point‐of‐care testing adoption, partnerships with public health agencies, and capacity expansion in emerging markets to support robust influenza diagnostic infrastructure worldwide.

Get Customization in the report as per your requirements:
https://www.datamintelligence.com/customize/influenza-diagnostics-market?sindhuri

Recent Key Developments - United States & North America
✅ June 2025: Abbott Laboratories launched next-generation rapid molecular influenza diagnostic tests with improved sensitivity and turnaround time, enhancing detection in hospitals and outpatient clinics across the U.S.
✅ May 2025: Quidel Corporation expanded its rapid influenza testing portfolio with point-of-care solutions integrated with digital reporting systems for real-time public health monitoring.
✅ 2025: Widespread adoption of rapid influenza diagnostics was driven by seasonal flu outbreaks, increasing demand for timely detection, and integration into emergency and urgent care facilities.

Recent Key Developments - Europe
✅ July 2025: Roche Diagnostics introduced advanced multiplex PCR platforms capable of detecting influenza A/B alongside other respiratory pathogens for European hospitals and diagnostic laboratories.
✅ Early 2026: bioMérieux strengthened its point-of-care influenza testing solutions in key European markets, supporting rapid screening during peak flu seasons.
✅ 2025: European healthcare providers increasingly adopted automated and high-throughput diagnostic platforms to improve influenza detection rates and patient management.

Recent Key Developments - Asia-Pacific
✅ June 2025: Fujirebio Inc. expanded rapid influenza test distribution in Japan and Southeast Asia, focusing on hospitals, clinics, and community health centers.
✅ 2025: SD Biosensor launched portable influenza diagnostic kits for on-site testing in schools, workplaces, and public health settings in China, India, and Australia.
✅ 2025-2026: Growing seasonal influenza prevalence, increased awareness of infectious disease management, and COVID-19 infrastructure leveraged for rapid testing drove regional market growth.

Recent Key Developments - Product & Technology Innovation
✅ Rapid Molecular & Antigen Tests: New assays deliver highly accurate results within minutes, enabling timely clinical decision-making.
✅ Multiplex & Syndromic Panels: Platforms capable of simultaneous detection of influenza and other respiratory viruses, supporting comprehensive pathogen identification.
✅ Digital Integration & Remote Reporting: Diagnostic devices integrated with cloud-based systems and EHRs facilitate epidemiological tracking and real-time reporting to public health authorities.

✅ 1. M&A / Strategic Activity
Recent strategic acquisitions and collaborations shaping the influenza diagnostics market:
Abbott Laboratories - Expansion of point‐of‐care diagnostics portfolio
Abbott strengthened its infectious disease testing capabilities by acquiring businesses and technologies that enhance rapid point‐of‐care platforms, integrating influenza testing with broader respiratory panels on versatile immunoassay and molecular systems.
Roche Diagnostics - Strategic partnerships for multiplex respiratory assays
Roche entered collaborations with reagent and molecular technology developers to broaden its cobas and Elecsys respiratory portfolios, including influenza A/B testing incorporated into multi‐pathogen respiratory panels for clinical and hospital labs.
Danaher (including Cepheid) - Strengthening molecular testing footprint
Danaher expanded its molecular diagnostics reach by acquiring or partnering with biotech firms specializing in advanced PCR and isothermal assay technologies, reinforcing Cepheid's GeneXpert platform with robust influenza detection modules.
bioMérieux - Alliance for integrated respiratory solutions
bioMérieux deepened strategic alliances with global labs and healthcare systems to deploy its BIOFIRE® FilmArray® multiplex respiratory panels which include influenza A/B and RSV enhancing infectious disease surveillance and differential diagnosis workflows.

✅ 2. New Product Launches & Regulatory Milestones
Recent product introductions, regulatory approvals, and service expansions in influenza diagnostics:
Abbott - BinaxNOWTM Influenza A & B Card
Abbott expanded availability of its BinaxNOWTM Influenza A & B Card as part of its point‐of‐care respiratory testing suite, providing rapid results that aid clinical decisions in outpatient, urgent care, and pharmacy settings.
Roche - cobas® Influenza A/B & RSV Test
Roche continued market launches of its cobas® Influenza A/B & RSV molecular test, enabling high‐throughput PCR testing with improved sensitivity and integrated data workflows for centralized lab environments.
Cepheid - Xpert® Xpress Flu/RSV Test
Cepheid received expanded clearances and broader adoption of its Xpert® Xpress Flu/RSV assay on GeneXpert platforms, offering rapid, multiplex molecular detection and simplified workflow for decentralized hospital labs and emergency departments.
bioMérieux - BIOFIRE® Respiratory Panel 2.1
bioMérieux's updated BIOFIRE® Respiratory Panel 2.1 continues to gain traction with expanded pathogen coverage that includes influenza A/B, novel strains, and differential markers critical for managing co‐circulating respiratory infections.
Regulatory Updates - Strengthened Surveillance Guidelines
Regulatory and public health bodies (e.g., WHO, CDC) have reinforced recommendations for influenza surveillance and rapid diagnostics - particularly in the context of respiratory disease seasonality and integrated testing for influenza, SARS‐CoV‐2, and other pathogens.

✅ 3. R&D & Technological Advancements
Multiplex & Syndromic Testing Platforms
R&D is increasingly focused on multiplex respiratory panels that simultaneously detect influenza A/B, RSV, SARS‐CoV‐2, and other pathogens, supporting differential diagnosis and improved clinical triage.
Digital & Cloud‐Enabled Diagnostics
Integration of cloud connectivity, digital reporting dashboards, and remote data analytics enables real‐time surveillance, rapid outbreak tracking, and improved laboratory workflow efficiencies for influenza test results.
Isothermal Amplification & Ultra‐Rapid Molecular Assays
Advances in isothermal nucleic acid amplification technologies enable ultra‐rapid molecular influenza tests (

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.